A Dose-range Finding Study of MAA868 in Patients With Atrial Fibrillation

Summary

This study is a multicenter, randomized, subject and Investigator-blinded, placebo-controlled, parallel-group, multiple ascending dose-ranging study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) effects of MAA868 in patients with atrial fibrillation (AF) or flutter at low risk of thromboembolic stroke or peripheral embolism.

Timeline

Start

2019-12-11

Primary completion

2020-12-29

Completion

2021-03-08

Drugs

Indications